An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma (GlofitReal)

Roche

Status: Enrolling

Conditions: Diffuse Large B-Cell Lymphoma

Treatments: Drug: Glofitamab

Study type: Observational

Funder types: Industry

Identifiers

NCT07200375

ML45172

Details and patient eligibility

About

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed R/R DLBCL after one line of systemic therapy
• Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment

Exclusion criteria

• Participants who currently participate in or plan to participate in any interventional clinical trial

Trial design

300 participants in 1 patient group

Glofitamab treatment

Description:

Participants will be enrolled into the study either prior to initiation of glofitamab therapy or within 90 days of starting glofitamab therapy.

Treatment:

Drug: Glofitamab